Decay characteristics of HIV-1-infected compartments during combination therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-05

AUTHORS

Alan S. Perelson, Paulina Essunger, Yunzhen Cao, Mika Vesanen, Arlene Hurley, Kalle Saksela, Martin Markowitz, David D. Ho

ABSTRACT

Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1–3. The concentration of HIV-1 in plasma drops by ∼99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of ≤6 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1–4weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5–2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3–3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites. More... »

PAGES

188-191

Journal

TITLE

Nature

ISSUE

6629

VOLUME

387

Related Patents

  • Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolitic Products
  • Methods For Measuring Rates Of Reverse Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis
  • Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Administering Isotope Labeled Water To Tissue; Measurement; Calibration
  • Primers, Probes And Methods For Sensitive, Specific Detection And Monitoring Of Hiv-1 And Hcv
  • Measurement Of Cell Prolferation Or Cell Destruction; Obtain Cells, Incubate With Labeled Nucleotides Sequences, Detect Labeled Nucleotides In Cells
  • Methods Of Treating Hiv And Aids And The Elimination Of Latent Reservoirs Of Hiv Infection Using Selectin, Galectin, And Siglec Antagonists
  • Metabolic Flux Measurement, Imaging And Microscopy
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Method For Replacing Biomarkers Of Protein Kinetics From Tissue Samples By Biomarkers Of Protein Kinetics From Body Fluids After Isotopic Labeling In Vivo
  • Expression Of Hiv Polypeptides And Production Of Virus-Like Particles
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis
  • Assay For Detecting Human Immunodeficiency Virus (Hiv)
  • Measuring Isotope Labelled Dna Synthesis And Destruction; Cancer Diagnosis; Prognosing Human Immunodeficiency Virus
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Methods Of Monitoring Treatment Effectiveness In Hiv-Infected Patients Receiveing Intensified Haart Regimens By Measuring Episomal 2-Ltr Circles
  • Monitoring Two Dimensions Of Diabetes Pathogenesis
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Methods For Determining Total Body Skeletal Muscle Mass
  • Compositions And Methods Related To Characterizing Proviral Reservoirs
  • Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems
  • Methods For Identifying The Effect Of A Drug Agent On The Metabolism Of Sugars And Fats In An Individual
  • Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/387188a0

    DOI

    http://dx.doi.org/10.1038/387188a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1026180202

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9144290


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Microbiology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anti-HIV Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CD4-Positive T-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy, Combination", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Infections", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Protease Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV-1", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Isoquinolines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lamivudine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukocytes, Mononuclear", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Macrophages", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mathematics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Biological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nelfinavir", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proviruses", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA, Viral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Reverse Transcriptase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulfonic Acids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Viral Load", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Viremia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Virus Latency", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Zidovudine", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perelson", 
            "givenName": "Alan S.", 
            "id": "sg:person.01335541022.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335541022.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Essunger", 
            "givenName": "Paulina", 
            "id": "sg:person.01342367032.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342367032.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cao", 
            "givenName": "Yunzhen", 
            "id": "sg:person.01343017451.31", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343017451.31"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vesanen", 
            "givenName": "Mika", 
            "id": "sg:person.01370270152.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370270152.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hurley", 
            "givenName": "Arlene", 
            "id": "sg:person.01154520206.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154520206.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Saksela", 
            "givenName": "Kalle", 
            "id": "sg:person.01172560566.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172560566.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Markowitz", 
            "givenName": "Martin", 
            "id": "sg:person.016673513377.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673513377.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ho", 
            "givenName": "David D.", 
            "id": "sg:person.01342202624.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342202624.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/360264a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017658165", 
              "https://doi.org/10.1038/360264a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/373123a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014949926", 
              "https://doi.org/10.1038/373123a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1295-1284", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020288435", 
              "https://doi.org/10.1038/nm1295-1284"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/387183a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036513917", 
              "https://doi.org/10.1038/387183a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01468720", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005527589", 
              "https://doi.org/10.1007/bf01468720"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/377740a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020157720", 
              "https://doi.org/10.1038/377740a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1997-05", 
        "datePublishedReg": "1997-05-01", 
        "description": "Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1\u20133. The concentration of HIV-1 in plasma drops by \u223c99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of \u22646 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1\u20134weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5\u20132 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3\u20133.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/387188a0", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6629", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "387"
          }
        ], 
        "keywords": [
          "HIV-1", 
          "combination therapy", 
          "human immunodeficiency virus type 1", 
          "immunodeficiency virus type 1", 
          "initiation of treatment", 
          "weeks of treatment", 
          "potent antiretroviral agents", 
          "second-phase decay", 
          "virus type 1", 
          "plasma viraemia", 
          "viral load", 
          "antiretroviral agents", 
          "sanctuary site", 
          "type 1", 
          "free virus", 
          "longer treatment", 
          "rapid elimination", 
          "infected cells", 
          "viral compartments", 
          "inhibitory treatment", 
          "treatment", 
          "therapy", 
          "initial decrease", 
          "days3", 
          "cells", 
          "viraemia", 
          "compartments", 
          "HIV", 
          "major contributor", 
          "lymphocytes", 
          "weeks", 
          "virus", 
          "t1/2", 
          "activation", 
          "hours", 
          "loss", 
          "analysis of changes", 
          "initiation", 
          "agents", 
          "years", 
          "substantial insight", 
          "decrease", 
          "elimination", 
          "possible existence", 
          "analysis", 
          "contributor", 
          "second phase", 
          "changes", 
          "concentration", 
          "characteristics", 
          "sites", 
          "plasma drop", 
          "minor source", 
          "insights", 
          "drop", 
          "phase", 
          "load", 
          "source", 
          "existence", 
          "decay characteristics", 
          "decay", 
          "dynamics", 
          "mathematical analysis", 
          "detailed mathematical analysis"
        ], 
        "name": "Decay characteristics of HIV-1-infected compartments during combination therapy", 
        "pagination": "188-191", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1026180202"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/387188a0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9144290"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/387188a0", 
          "https://app.dimensions.ai/details/publication/pub.1026180202"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:52", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_299.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/387188a0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/387188a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    290 TRIPLES      21 PREDICATES      119 URIs      105 LITERALS      30 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/387188a0 schema:about N00453410c5004ffc8b5865dc1b51d8c5
    2 N00790515aa9e4ba79b9016818c14a554
    3 N0a1b9dca569942438206de5a87d3a737
    4 N1bad2e5462e9472d92f1cea9da71ebb2
    5 N25afb103be35476a93c730626f9ada58
    6 N2819de11a4ce49609d095ae66c501476
    7 N3b6032f9ffa34cabb3db6aff93fa1ed7
    8 N3f31b221f2054a5d891c81025434b31b
    9 N41ef7ef7fa11413a9b250ef8b982e3b0
    10 N5335762c6dc64b6a886c03ce74374b43
    11 N54bc8e247e1e4732bef18882dbc7bbbe
    12 N66a78f24ffe24f73b1a40bf2186a943d
    13 N6b8dd6291c7e4cd78549ddbdfc26693b
    14 N79285328c7e345eab09a41562f4cad44
    15 N7c24277a17ec4702869370b767533a77
    16 N9b0849af83534369aec078c558fa3155
    17 N9e093089429445e6a0cb91e72bbe49c0
    18 Nb25aa124bc2f4f64be28088ab91ffbd7
    19 Nb9d3816661174bbb9cc753a33433d73a
    20 Nea0beb5632854e97bc2bc90bbafdc851
    21 Ned4757c2d7fb48fd89b474c08d7ab230
    22 Nf288de63b64b4c6bbddfe0ce8bdec4a1
    23 Nf8db31e7dca547229153f72644b7307d
    24 anzsrc-for:11
    25 anzsrc-for:1108
    26 schema:author Na3a96d4c635f4947bc25544b9999b27b
    27 schema:citation sg:pub.10.1007/bf01468720
    28 sg:pub.10.1038/360264a0
    29 sg:pub.10.1038/373123a0
    30 sg:pub.10.1038/377740a0
    31 sg:pub.10.1038/387183a0
    32 sg:pub.10.1038/nm1295-1284
    33 schema:datePublished 1997-05
    34 schema:datePublishedReg 1997-05-01
    35 schema:description Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1–3. The concentration of HIV-1 in plasma drops by ∼99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of ≤6 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1–4weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5–2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3–3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.
    36 schema:genre article
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N2791dff4faab4bcca47cf1f4250c0234
    39 N4e2621178a11475abe3c51d85c6796bb
    40 sg:journal.1018957
    41 schema:keywords HIV
    42 HIV-1
    43 activation
    44 agents
    45 analysis
    46 analysis of changes
    47 antiretroviral agents
    48 cells
    49 changes
    50 characteristics
    51 combination therapy
    52 compartments
    53 concentration
    54 contributor
    55 days3
    56 decay
    57 decay characteristics
    58 decrease
    59 detailed mathematical analysis
    60 drop
    61 dynamics
    62 elimination
    63 existence
    64 free virus
    65 hours
    66 human immunodeficiency virus type 1
    67 immunodeficiency virus type 1
    68 infected cells
    69 inhibitory treatment
    70 initial decrease
    71 initiation
    72 initiation of treatment
    73 insights
    74 load
    75 longer treatment
    76 loss
    77 lymphocytes
    78 major contributor
    79 mathematical analysis
    80 minor source
    81 phase
    82 plasma drop
    83 plasma viraemia
    84 possible existence
    85 potent antiretroviral agents
    86 rapid elimination
    87 sanctuary site
    88 second phase
    89 second-phase decay
    90 sites
    91 source
    92 substantial insight
    93 t1/2
    94 therapy
    95 treatment
    96 type 1
    97 viraemia
    98 viral compartments
    99 viral load
    100 virus
    101 virus type 1
    102 weeks
    103 weeks of treatment
    104 years
    105 schema:name Decay characteristics of HIV-1-infected compartments during combination therapy
    106 schema:pagination 188-191
    107 schema:productId N721563b837244ffcb8c9aae642071587
    108 Na78caa56cced4b8dae40ea715fc477ce
    109 Nf662397025e1486fa2d987cecd88f7a6
    110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026180202
    111 https://doi.org/10.1038/387188a0
    112 schema:sdDatePublished 2022-08-04T16:52
    113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    114 schema:sdPublisher N9ca9b81d03894253aebb30ff43d47513
    115 schema:url https://doi.org/10.1038/387188a0
    116 sgo:license sg:explorer/license/
    117 sgo:sdDataset articles
    118 rdf:type schema:ScholarlyArticle
    119 N00453410c5004ffc8b5865dc1b51d8c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Anti-HIV Agents
    121 rdf:type schema:DefinedTerm
    122 N00790515aa9e4ba79b9016818c14a554 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Viremia
    124 rdf:type schema:DefinedTerm
    125 N0a1b9dca569942438206de5a87d3a737 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name HIV Protease Inhibitors
    127 rdf:type schema:DefinedTerm
    128 N1bad2e5462e9472d92f1cea9da71ebb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name CD4-Positive T-Lymphocytes
    130 rdf:type schema:DefinedTerm
    131 N25afb103be35476a93c730626f9ada58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Isoquinolines
    133 rdf:type schema:DefinedTerm
    134 N2791dff4faab4bcca47cf1f4250c0234 schema:issueNumber 6629
    135 rdf:type schema:PublicationIssue
    136 N2819de11a4ce49609d095ae66c501476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Viral Load
    138 rdf:type schema:DefinedTerm
    139 N3b6032f9ffa34cabb3db6aff93fa1ed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Zidovudine
    141 rdf:type schema:DefinedTerm
    142 N3c231531206c46ff988d89090d36090e rdf:first sg:person.016673513377.34
    143 rdf:rest N6b74dec712eb469b982b9ba7b1136218
    144 N3f31b221f2054a5d891c81025434b31b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name HIV Infections
    146 rdf:type schema:DefinedTerm
    147 N41ef7ef7fa11413a9b250ef8b982e3b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Models, Biological
    149 rdf:type schema:DefinedTerm
    150 N4afc1f17d7ce44a8bc7a692e4b209064 rdf:first sg:person.01370270152.62
    151 rdf:rest N544e3b0fec794a62a4d8763be6dd4895
    152 N4e2621178a11475abe3c51d85c6796bb schema:volumeNumber 387
    153 rdf:type schema:PublicationVolume
    154 N5335762c6dc64b6a886c03ce74374b43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Drug Therapy, Combination
    156 rdf:type schema:DefinedTerm
    157 N544e3b0fec794a62a4d8763be6dd4895 rdf:first sg:person.01154520206.45
    158 rdf:rest Nbfd35f1d3d4341f19afbc7b61a90b2bc
    159 N54bc8e247e1e4732bef18882dbc7bbbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name HIV-1
    161 rdf:type schema:DefinedTerm
    162 N57610ae9c9504ba6bee7f9d08b90de58 rdf:first sg:person.01342367032.44
    163 rdf:rest Nf819cb4a2aa24f5880821b73507352d5
    164 N66a78f24ffe24f73b1a40bf2186a943d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Macrophages
    166 rdf:type schema:DefinedTerm
    167 N6b74dec712eb469b982b9ba7b1136218 rdf:first sg:person.01342202624.34
    168 rdf:rest rdf:nil
    169 N6b8dd6291c7e4cd78549ddbdfc26693b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name RNA, Viral
    171 rdf:type schema:DefinedTerm
    172 N721563b837244ffcb8c9aae642071587 schema:name dimensions_id
    173 schema:value pub.1026180202
    174 rdf:type schema:PropertyValue
    175 N79285328c7e345eab09a41562f4cad44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Leukocytes, Mononuclear
    177 rdf:type schema:DefinedTerm
    178 N7c24277a17ec4702869370b767533a77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Mathematics
    180 rdf:type schema:DefinedTerm
    181 N9b0849af83534369aec078c558fa3155 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Virus Latency
    183 rdf:type schema:DefinedTerm
    184 N9ca9b81d03894253aebb30ff43d47513 schema:name Springer Nature - SN SciGraph project
    185 rdf:type schema:Organization
    186 N9e093089429445e6a0cb91e72bbe49c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Reverse Transcriptase Inhibitors
    188 rdf:type schema:DefinedTerm
    189 Na3a96d4c635f4947bc25544b9999b27b rdf:first sg:person.01335541022.50
    190 rdf:rest N57610ae9c9504ba6bee7f9d08b90de58
    191 Na78caa56cced4b8dae40ea715fc477ce schema:name doi
    192 schema:value 10.1038/387188a0
    193 rdf:type schema:PropertyValue
    194 Nb25aa124bc2f4f64be28088ab91ffbd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Humans
    196 rdf:type schema:DefinedTerm
    197 Nb9d3816661174bbb9cc753a33433d73a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Sulfonic Acids
    199 rdf:type schema:DefinedTerm
    200 Nbfd35f1d3d4341f19afbc7b61a90b2bc rdf:first sg:person.01172560566.03
    201 rdf:rest N3c231531206c46ff988d89090d36090e
    202 Nea0beb5632854e97bc2bc90bbafdc851 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Nelfinavir
    204 rdf:type schema:DefinedTerm
    205 Ned4757c2d7fb48fd89b474c08d7ab230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Lamivudine
    207 rdf:type schema:DefinedTerm
    208 Nf288de63b64b4c6bbddfe0ce8bdec4a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Proviruses
    210 rdf:type schema:DefinedTerm
    211 Nf662397025e1486fa2d987cecd88f7a6 schema:name pubmed_id
    212 schema:value 9144290
    213 rdf:type schema:PropertyValue
    214 Nf819cb4a2aa24f5880821b73507352d5 rdf:first sg:person.01343017451.31
    215 rdf:rest N4afc1f17d7ce44a8bc7a692e4b209064
    216 Nf8db31e7dca547229153f72644b7307d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Half-Life
    218 rdf:type schema:DefinedTerm
    219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    220 schema:name Medical and Health Sciences
    221 rdf:type schema:DefinedTerm
    222 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
    223 schema:name Medical Microbiology
    224 rdf:type schema:DefinedTerm
    225 sg:journal.1018957 schema:issn 0028-0836
    226 1476-4687
    227 schema:name Nature
    228 schema:publisher Springer Nature
    229 rdf:type schema:Periodical
    230 sg:person.01154520206.45 schema:affiliation grid-institutes:grid.148313.c
    231 schema:familyName Hurley
    232 schema:givenName Arlene
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154520206.45
    234 rdf:type schema:Person
    235 sg:person.01172560566.03 schema:affiliation grid-institutes:grid.148313.c
    236 schema:familyName Saksela
    237 schema:givenName Kalle
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172560566.03
    239 rdf:type schema:Person
    240 sg:person.01335541022.50 schema:affiliation grid-institutes:grid.148313.c
    241 schema:familyName Perelson
    242 schema:givenName Alan S.
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335541022.50
    244 rdf:type schema:Person
    245 sg:person.01342202624.34 schema:affiliation grid-institutes:grid.148313.c
    246 schema:familyName Ho
    247 schema:givenName David D.
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342202624.34
    249 rdf:type schema:Person
    250 sg:person.01342367032.44 schema:affiliation grid-institutes:grid.148313.c
    251 schema:familyName Essunger
    252 schema:givenName Paulina
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342367032.44
    254 rdf:type schema:Person
    255 sg:person.01343017451.31 schema:affiliation grid-institutes:grid.148313.c
    256 schema:familyName Cao
    257 schema:givenName Yunzhen
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343017451.31
    259 rdf:type schema:Person
    260 sg:person.01370270152.62 schema:affiliation grid-institutes:grid.148313.c
    261 schema:familyName Vesanen
    262 schema:givenName Mika
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370270152.62
    264 rdf:type schema:Person
    265 sg:person.016673513377.34 schema:affiliation grid-institutes:grid.148313.c
    266 schema:familyName Markowitz
    267 schema:givenName Martin
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673513377.34
    269 rdf:type schema:Person
    270 sg:pub.10.1007/bf01468720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005527589
    271 https://doi.org/10.1007/bf01468720
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/360264a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017658165
    274 https://doi.org/10.1038/360264a0
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/373123a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014949926
    277 https://doi.org/10.1038/373123a0
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/377740a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020157720
    280 https://doi.org/10.1038/377740a0
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/387183a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036513917
    283 https://doi.org/10.1038/387183a0
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/nm1295-1284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020288435
    286 https://doi.org/10.1038/nm1295-1284
    287 rdf:type schema:CreativeWork
    288 grid-institutes:grid.148313.c schema:alternateName Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA
    289 schema:name Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA
    290 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...